Prognostic significance of body mass index and weight loss in patients with idiopathic pleuroparenchymal fibroelastosis
Main Article Content
Keywords
Body mass index, Weight loss, Idiopathic pleuroparenchymal fibroelastosis, Prognosis
Abstract
Background and aim: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare form of idiopathic interstitial pneumonias; its physical characteristics include a slender build with platythorax and progressive weight loss. However, the clinical significance of body mass index (BMI) and weight loss remains unclear in patients with IPPFE. Therefore, we aimed to clarify the association between baseline BMI, weight loss after diagnosis, and the prognosis of patients with IPPFE. Methods: This retrospective study included 71 patients diagnosed with IPPFE at our institution between 2005–2021. BMI at diagnosis was classified into three: underweight (<18.5 kg/m2), normal weight (≥18.5 to <25.0 kg/m2), or overweight (≥25.0 kg/m2). An annual rate of weight change after the diagnosis was evaluated, and ≥5% per year decrease was defined as a significant weight loss. We investigated clinical features and prognosis based on baseline BMI and weight loss. Results: Of the 71 patients, 48 (67.6%) and 23 (32.4%) were classified as underweight and normal weight, respectively, and none were overweight. Significant weight loss occurred in 24 (33.8%) patients, and they tended to have more cases of dyspnea and had significantly older age, lower BMI, higher rates of co-existence of lower-lobe interstitial lung disease, lower pulmonary function test results and higher incidence of pneumothorax after the diagnosis than those without weight loss. Patients with BMI <18.5 kg/m2 and those with weight loss had a significantly worse prognosis than those with BMI ≥18.5 kg/m2 or those without weight loss, respectively (p=0.005, p<0.001). Multivariate analysis revealed that low BMI and weight loss were independent poor prognostic factors. Conclusions: Low BMI and weight loss are associated with poor prognosis in patients with IPPFE.
References
2. Watanabe K. Pleuroparenchymal fibroelastosis: its clinical characteristics. Curr Respir Med Rev 2013; 9: 229–37.
3. Bonifazi M, Montero MA, Renzoni EA. Idiopathic pleuroparenchymal fibroelastosis. Curr Pulmonol Rep 2017; 6: 9–15.
4. Chua F, Desai SR, Nicholson AG, et al. Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics. Ann Am Thorac Soc 2019; 16: 1351–9.
5. Kinoshita Y, Ishii H, Nabeshima K, Watanabe K. The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis. Histol Histopathol 2021; 36: 291–303.
6. Cottin V, Si-Mohamed S, Diesler R, Bonniaud P, Valenzuela C. Pleuroparenchymal fibroelastosis. Curr Opin Pulm Med 2022; 28: 432–40.
7. Fujisawa T, Mori K, Mikamo M, et al. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. Eur Respir J 2019; 53: 1802243.
8. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev 2019; 28: 180100.
9. Kono M, Nakamura Y, Enomoto Y, et al. Pneumothorax in patients with idiopathic pleuroparenchymal fibroelastosis: incidence, clinical features, and risk factors. Respiration 2021; 100: 19–26.
10. Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 1448–53.
11. Jouneau S, Crestani B, Thibault R, et al. Post hoc analysis of clinical outcomes in placebo- and pirfenidone-treated patients with IPF stratified by BMI and weight Loss. Respiration 2022; 101: 142–54.
12. Comes A, Wong AW, Fisher JH, et al. Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease Chest 2022; 161: 1320–9.
13. Jouneau S, Rousseau C, Lederlin M, et al. Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clin Nutr 2022; 41: 1335–42.
14. Pugashetti J, Graham J, Boctor N, et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J 2018; 52: 1801289.
15. Nakatsuka Y, Handa T, Kokosi M, et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration 2018; 96: 338–47.
16. Kulkarni T, Yuan K, Tran-Nguyen TK, et al. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS One 2019; 14: e0221905.
17. Jouneau S, Crestani B, Thibault R, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res 2020; 21: 312.
18. Kinoshita Y, Utsunomiya T, Koide Y, et al. Changes in body weight reflect disease progression in pleuroparenchymal fibroelastosis. Respir Med Res 2022; 83: 100980.
19. Enomoto Y, Nakamura Y, Satake Y, et al. Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study. Respir Med 2017; 133: 1–5.
20. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018; 6: 138–53.
21. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–12.
22. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS ONE 2012; 7: e43892.
23. Hayashi H, Nei T, Abe S, et al. Body mass index and arterial blood oxygenation as prognostic factors in patients with idiopathic pleuroparenchymal fibroelastosis. Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 35–40.
24. Suzuki Y, Yoshimura K, Enomoto Y, et al. Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis. Sci Rep 2018; 8: 14074.
25. Ishii H, Watanabe K, Kushima H, Baba T, Watanabe S, Yamada Y. Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan. Respir Med 2018; 141: 190–7.
26. Kono M, Tsunoda T, Ikeda S, et al. Clinical features of idiopathic pleuroparenchymal fibroelastosis with progressive phenotype showing a decline in forced vital capacity. Respir Investig 2023; 61: 210–9.
27. Nasser M, Si-Mohamed S, Turquier S, et al. Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis. Orphanet J Rare Dis 2021; 16: 419.
28. Kinoshita Y, Miyamura T, Ikeda T, et al. Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis. Respir Investig 2022; 60: 562–9.
29. Mori Y, Yamano Y, Kataoka K, et al. Pulmonary rehabilitation for idiopathic pleuroparenchymal fibroelastosis: A retrospective study on its efficacy, feasibility, and safety. Respir Investig 2021; 59: 849–58.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
